Brief: G1 Therapeutics Provides Update On Phase 3 Preserve 2 Trial

G1 Therapeutics

24/06/2024 11:33

June 24 (Reuters) - G1 Therapeutics Inc  GTHX.O :
    * G1 THERAPEUTICS PROVIDES UPDATE ON PHASE 3 PRESERVE 2
TRIAL IN
PATIENTS RECEIVING TRILACICLIB PRIOR TO FIRST LINE CHEMOTHERAPY
IN METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC)
    * G1 THERAPEUTICS INC - G1 IS SUFFICIENTLY FUNDED TO ACHIEVE
ANTICIPATED COMPANY PROFITABILITY IN SECOND HALF OF 2025
    * G1 THERAPEUTICS PHASE 3 TRIAL FAILS TO MEET OS
    * G1 THERAPEUTICS PLANS TARGETED HEADCOUNT REDUCTIONS
    * G1 THERAPEUTICS INC - REAFFIRMED ITS FULL YEAR 2024 COSELA
NET
REVENUE GUIDANCE AND UPDATED ITS CASH RUNWAY GUIDANCE
    * G1 THERAPEUTICS INC - EFFORTS EXPECTED TO PROVIDE
SUFFICIENT
CASH RUNWAY TO ACHIEVE ANTICIPATED COMPANY PROFITABILITY IN
SECOND HALF OF 2025
    * G1: TO WIND DOWN PHASE 3 PRESERVE 2 TRIAL, DISCONTINUE
ANTICIPATED HIRING OF STAFF AND INVESTMENT FOR A 1L TNBC
INDICATION

Source text for Eikon:  ID:nGNX3P3LTz 
Further company coverage:  GTHX.O 

 ((Reuters.Briefs@thomsonreuters.com;))